Vascular Risk in Chronic Obstructive Pulmonary Disease: Role of Inflammation and Other Mediators

Canadian Journal of Cardiology

Volumn 28, Issue 6, 2012, Pages 653-661

  Man, S F Paul ^a   Van Eeden, Stephan ^a   Sin, Don D ^a  

^a ST PAUL S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; INFLUENZA VACCINE; INTERLEUKIN 6; SURFACTANT PROTEIN D;

AIR QUALITY; ASTHMA; ATHEROSCLEROSIS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COUGHING; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSPNEA; EMPHYSEMA; FAMILIAL HYPERLIPEMIA; FORCED EXPIRATORY VOLUME; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATORY CELL; INFLUENZA; INFLUENZA VACCINATION; ISCHEMIC HEART DISEASE; LYMPHOCYTE; NEUTROPHIL; NONHUMAN; PNEUMONIA; REVIEW; RISK ASSESSMENT; SMOKING; SMOKING CESSATION; SPIROMETRY; SPUTUM; THROMBOSIS; URINARY TRACT INFECTION;

ANIMALS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; INCIDENCE; INFLAMMATION; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; VASCULAR DISEASES; WORLD HEALTH;

EID: 84869095593     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2012.06.013     Document Type: Review

References (81)

1. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
2. Lopez-Pedrera C., Perez-Sanchez C., Ramos-Casals M., Santos-Gonzalez M., Rodriguez-Ariza A., Cuadrado M.J. Cardiovascular risk in systemic autoimmune diseases: epigenetic mechanisms of immune regulatory functions [published online September 14, 2011]. Clin Dev Immunol Accessed June 22, 2012. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3173726/?tool=pubmed.
3. Bisoendial R.J., Stroes E.S., Tak P.P. Critical determinants of cardiovascular risk in rheumatoid arthritis. Curr Pharm Des 2011, 17:21-26.
4. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
5. Roifman I., Beck P.L., Anderson T.J., Eisenberg M.J., Genest J. Chronic inflammatory diseases and cardiovascular risk: a systematic review. Can J Cardiol 2011, 27:174-182.
6. Sin D.D., Wu L., Man S.F. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005, 127:1952-1959.
7. Rabe K.F., Hurd S., Anzueto A., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176:532-555.
8. Lamprecht B., McBurnie M.A., Vollmer W.M., et al. COPD in never smokers: results from the population-based Burden of Obstructive Lung Disease study. Chest 2011, 139:752-763.
9. de Marco R., Accordini S., Marcon A., et al. Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults. Am J Respir Crit Care Med 2011, 183:891-897.
10. Vestbo J., Edwards L.D., Scanlon P.D., et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011, 365:1184-1192.
11. Pelkonen M., Notkola I.L., Nissinen A., Tukiainen H., Koskela H. Thirty-year cumulative incidence of chronic bronchitis and COPD in relation to 30-year pulmonary function and 40-year mortality: a follow-up in middle-aged rural men. Chest 2006, 130:1129-1137.
12. McDonough J.E., Yuan R., Suzuki M., et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med 2011, 365:1567-1575.
13. Willemse B.W., ten Hacken N.H., Rutgers B., Lesman-Leegte I.G., Postma D.S., Timens W. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J 2005, 26:835-845.
14. Hogg J.C., Chu F., Utokaparch S., et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:2645-2653.
15. Gan W.Q., Man S.F., Senthilselvan A., Sin D.D. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004, 59:574-580.
16. Sin D.D., Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases?. the potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003, 107:1514-1519.
17. Hastie C.E., Haw S., Pell J.P. Impact of smoking cessation and lifetime exposure on C-reactive protein. Nicotine Tob Res 2008, 10:637-642.
18. Sze M.A., Dimitriu P.A., Hayashi S., et al. The lung tissue microbiome in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 185:1073-1080.
19. Lee S.H., Goswami S., Grudo A., et al. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 2007, 13:567-569.
20. Snelgrove R.J., Jackson P.L., Hardison M.T., et al. A critical role for LTA4H in limiting chronic pulmonary neutrophilic inflammation. Science 2010, 330:90-94.
21. Friedman G.D., Klatsky A.L., Siegelaub A.B. Lung function and risk of myocardial infarction and sudden cardiac death. N Engl J Med 1976, 294:1071-1075.
22. Smeeth L., Thomas S.L., Hall A.J., Hubbard R., Farrington P., Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004, 351:2611-2618.
23. Finkelstein J., Cha E., Scharf S.M. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis 2009, 4:337-349.
24. Huiart L., Ernst P., Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005, 128:2640-2646.
25. Sidney S., Sorel M., Quesenberry C.P., DeLuise C., Lanes S., Eisner M.D. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005, 128:2068-2075.
26. Curkendall S.M., DeLuise C., Jones J.K., et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006, 16:63-70.
27. Schneider C., Bothner U., Jick S.S., Meier C.R. Chronic obstructive pulmonary disease and the risk of cardiovascular diseases. Eur J Epidemiol 2010, 25:253-260.
28. Hole D.J., Watt G.C., Davey-Smith G., Hart C.L., Gillis C.R., Hawthorne V.M. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996, 313:711-715. [discussion: 5-6].
29. Pope C.A., Burnett R.T., Krewski D., et al. Cardiovascular mortality and exposure to airborne fine particulate matter and cigarette smoke: shape of the exposure-response relationship. Circulation 2009, 120:941-948.
30. Stevenson K., Kent A., Maggs R., Harrison D. Measurement of PM10 and PM2.5 in Scotland with gravimetric samplers Accessed June 22, 2012. http://www.scottishairquality.co.uk/documents/reports2/242090615_Scottish_Partisol_Report_Issue_1_12-06-09.pdf.
31. Soriano J.B., Rigo F., Guerrero D., et al. High prevalence of undiagnosed airflow limitation in patients with cardiovascular disease. Chest 2010, 137:333-340.
32. Anthonisen N.R., Connett J.E., Kiley J.P., et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA 1994, 272:1497-1505.
33. Anthonisen N.R., Connett J.E., Enright P.L., Manfreda J. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002, 166:333-339.
34. He Z., Chen Y., Chen P., Wu G., Cai S. Local inflammation occurs before systemic inflammation in patients with COPD. Respirology 2010, 15:478-484.
35. Hill J., Heslop C., Man S.F., et al. Circulating surfactant protein-D and the risk of cardiovascular morbidity and mortality. Eur Heart J 2011, 32:1918-1925.
36. van Eeden S.F., Sin D.D. Chronic obstructive pulmonary disease: a chronic systemic inflammatory disease. Respiration 2008, 75:224-238.
37. Danesh J., Kaptoge S., Mann A.G., et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 2008, 5:e78.
38. Kaptoge S., Di Angelantonio E., et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010, 375:132-140. Emerging Risk Factors Collaboration.
39. Churg A., Sin D.D., Wright J.L. Everything prevents emphysema: are animal models of cigarette smoke-induced chronic obstructive pulmonary disease any use?. Am J Respir Cell Mol Biol 2011, 45:1111-1115.
40. Botelho F.M., Gaschler G.J., Kianpour S., et al. Innate immune processes are sufficient for driving cigarette smoke-induced inflammation in mice. Am J Respir Cell Mol Biol 2010, 42:394-403.
41. Coates A.L. Guiding aerosol deposition in the lung. N Engl J Med 2008, 358:304-305.
42. Ching I., Dunn-Rankin D. Light scattering measurements of cigarette smoke. Aerosol Sci Tech 1996, 24:85-101.
43. Countess R.J., Cadle S.H., Groblicki P.J., Wolff G.T. Chemical analysis of size-segregated samples of Denver's ambient particulate. J Air Pollut Control Assoc 1981, 31:247-252.
44. Jerrett M., Burnett R.T., Pope C.A., et al. Long-term ozone exposure and mortality. N Engl J Med 2009, 360:1085-1095.
45. Pope C.A., Ezzati M., Dockery D.W. Fine-particulate air pollution and life expectancy in the United States. N Engl J Med 2009, 360:376-386.
46. Miller K.A., Siscovick D.S., Sheppard L., et al. Long-term exposure to air pollution and incidence of cardiovascular events in women. N Engl J Med 2007, 356:447-458.
47. Lipsett M.J., Ostro B.D., Reynolds P., et al. Long-term exposure to air pollution and cardiorespiratory disease in the California teachers study cohort. Am J Respir Crit Care Med 2011, 184:828-835.
48. Dominici F., Peng R.D., Bell M.L., et al. Fine particulate air pollution and hospital admission for cardiovascular and respiratory diseases. JAMA 2006, 295:1127-1134.
49. Suwa T., Hogg J.C., Quinlan K.B., Ohgami A., Vincent R., van Eeden S.F. Particulate air pollution induces progression of atherosclerosis. J Am Coll Cardiol 2002, 39:935-942.
50. Gairola C.G., Drawdy M.L., Block A.E., Daugherty A. Sidestream cigarette smoke accelerates atherogenesis in apolipoprotein E-/- mice. Atherosclerosis 2001, 156:49-55.
51. von Holt K., Lebrun S., Stinn W., Conroy L., Wallerath T., Schleef R. Progression of atherosclerosis in the apo E-/- model: 12-month exposure to cigarette mainstream smoke combined with high-cholesterol/fat diet. Atherosclerosis 2009, 205:135-143.
52. Bai N., Kido T., Suzuki H., et al. Changes in atherosclerotic plaques induced by inhalation of diesel exhaust. Atherosclerosis 2011, 216:299-306.
53. Sun Q., Wang A., Jin X., et al. Long-term air pollution exposure and acceleration of atherosclerosis and vascular inflammation in an animal model. JAMA 2005, 294:3003-3010.
54. Swiston J.R., Davidson W., Attridge S., Li G.T., Brauer M., van Eeden S.F. Wood smoke exposure induces a pulmonary and systemic inflammatory response in firefighters. Eur Respir J 2008, 32:129-138.
55. Mills N.L., Tornqvist H., Gonzalez M.C., et al. Ischemic and thrombotic effects of dilute diesel-exhaust inhalation in men with coronary heart disease. N Engl J Med 2007, 357:1075-1082.
56. Mills N.L., Tornqvist H., Robinson S.D., et al. Diesel exhaust inhalation causes vascular dysfunction and impaired endogenous fibrinolysis. Circulation 2005, 112:3930-3936.
57. Rosengren A., Anderson K., Wilhelmsen L. Risk of coronary heart disease in middle-aged male bus and tram drivers compared to men in other occupations: a prospective study. Int J Epidemiol 1991, 20:82-87.
58. Peters A., Dockery D.W., Muller J.E., Mittleman M.A. Increased particulate air pollution and the triggering of myocardial infarction. Circulation 2001, 103:2810-2815.
59. Sullivan J., Sheppard L., Schreuder A., Ishikawa N., Siscovick D., Kaufman J. Relation between short-term fine-particulate matter exposure and onset of myocardial infarction. Epidemiology 2005, 16:41-48.
60. Pope C.A., Muhlestein J.B., May H.T., Renlund D.G., Anderson J.L., Horne B.D. Ischemic heart disease events triggered by short-term exposure to fine particulate air pollution. Circulation 2006, 114:2443-2448.
61. Donaldson G.C., Hurst J.R., Smith C.J., Hubbard R.B., Wedzicha J.A. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010, 137:1091-1097.
62. Wedzicha J.A., Seemungal T.A. COPD exacerbations: defining their cause and prevention. Lancet 2007, 370:786-796.
63. Phrommintikul A., Kuanprasert S., Wongcharoen W., Kanjanavanit R., Chaiwarith R., Sukonthasarn A. Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. Eur Heart J 2011, 32:1730-1735.
64. Mutlu G.M., Green D., Bellmeyer A., et al. Ambient particulate matter accelerates coagulation via an IL-6-dependent pathway. J Clin Invest 2007, 117:2952-2961.
65. Kido T., Tamagawa E., Bai N., et al. Particulate matter induces translocation of IL-6 from the lung to the systemic circulation. Am J Respir Cell Mol Biol 2011, 44:197-204.
66. Suda K., Tsuruta M., Eom J., et al. Acute lung injury induces cardiovascular dysfunction: effects of IL-6 and budesonide/formoterol. Am J Respir Cell Mol Biol 2011, 45:510-516.
67. Suda K., Eom J., Jaw J.E., et al. Endotoxin-induced cardiovascular dysfunction in mice: effect of simvastatin. J Appl Physiol 2011, 111:1118-1124.
68. Ek A., Palmberg L., Larsson K. The effect of fluticasone on the airway inflammatory response to organic dust. Eur Respir J 2004, 24:587-593.
69. Bakhru A., Erlinger T.P. Smoking cessation and cardiovascular disease risk factors: results from the Third National Health and Nutrition Examination Survey. PLoS Med 2005, 2:e160.
70. Pell J.P., Haw S., Cobbe S., et al. Smoke-free legislation and hospitalizations for acute coronary syndrome. N Engl J Med 2008, 359:482-491.
71. Stefan M.S., Bannuru R.R., Lessard D., Gore J.M., Lindenauer P.K., Goldberg R.J. The impact of COPD on management and outcomes of patients hospitalized with acute myocardial infarction-a ten-year retrospective observational study. Chest 2012, 141:1441-1448.
72. Short P.M., Lipworth S.I., Elder D.H., Schembri S., Lipworth B.J. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ 2011, 342:d2549.
73. Rutten F.H., Zuithoff N.P., Hak E., Grobbee D.E., Hoes A.W. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010, 170:880-887.
74. van Gestel Y.R., Hoeks S.E., Sin D.D., et al. Impact of cardioselective beta-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med 2008, 178:695-700.
75. Brooks T.W., Creekmore F.M., Young D.C., Asche C.V., Oberg B., Samuelson W.M. Rates of hospitalizations and emergency department visits in patients with asthma and chronic obstructive pulmonary disease taking beta-blockers. Pharmacotherapy 2007, 27:684-690.
76. Dransfield M.T., Rowe S.M., Johnson J.E., Bailey W.C., Gerald L.B. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax 2008, 63:301-305.
77. Au D.H., Bryson C.L., Fan V.S., et al. Beta-blockers as single-agent therapy for hypertension and the risk of mortality among patients with chronic obstructive pulmonary disease. Am J Med 2004, 117:925-931.
78. Chen J., Radford M.J., Wang Y., Marciniak T.A., Krumholz H.M. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol 2001, 37:1950-1956.
79. Jabbour A., Macdonald P.S., Keogh A.M., et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol 2010, 55:1780-1787.
80. Kjeldsen S.E., Dahlof B., Devereux R.B., et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002, 288:1491-1498.
81. Podowski M., Calvi C., Metzger S., et al. Angiotensin receptor blockade attenuates cigarette smoke-induced lung injury and rescues lung architecture in mice. J Clin Invest 2012, 122:229-240.